Janux Therapeutics, Inc.JANXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.00% | -100.00% | -100.00% | +2177.90% | +0.00% |
| Gross Profit Growth | -100.00% | -100.00% | -100.00% | +2063.78% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +21.74% | +25.98% | +13.68% | +13.54% | +9.03% |
| Weighted Average Shares Diluted Growth | +21.74% | +25.98% | +13.68% | +13.54% | +9.03% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +26.79% | -52.80% | +41.78% | +19.46% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +179.05% | +52.51% | +49.29% | +47.44% | -5.65% |
| Book Value per Share Growth | +143.98% | +22.56% | +32.48% | +31.10% | -14.20% |
| Debt Growth | -6.18% | -6.50% | -6.84% | -3.29% | +81.91% |
| R&D Expense Growth | +69.97% | +78.07% | +132.68% | +86.04% | +51.63% |
| SG&A Expenses Growth | +29.24% | +44.50% | +42.91% | -42.71% | +32.10% |